Experimental and computational examination of anastellin (FnIII1c)–polymer interactions
Source abstract
Abstract
Abstract Using a combination of experimental and computational approaches, the interaction between anastellin, a recombinant fragment of fibronectin, and representative biomaterial surfaces has been examined. Anastellin and superfibronectin have been seen to exhibit antiangiogenic properties and other properties that may make it suitable for consideration for incorporation into biomaterials. The molecular interaction was directly quantified by atomic force microscope (AFM)‐based force spectroscopy, complemented by adsorption measurements using quartz crystal microbalance (QCM). Using AFM, it was found that the anastellin molecule facilitates a stronger adhesion on polyurethane films (72.0 pN nm−1) than on poly (methyl methacrylate) films (68.6 pN nm−1). However, this is not consistent with the QCM adsorption measurements, which show no significant difference. Molecular dynamics simulations of the behavior of anastellin on polyurethane in aqueous solution were performed to rationalize the experimental data, and show that anastellin is capable of rapid adsorption to PU while its secondary structure is stable upon adsorption in water. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 737–745, 2017.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cell Adhesion Molecules Research · Force Microscopy Techniques and Applications · Cellular Mechanics and Interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) University of Strathclyde 161 Cathedral Street Glasgow United Kingdom
School of Chemistry National University of Ireland Galway, University Road Galway Ireland
School of Chemical Engineering University of Birmingham Edgbaston Birmingham United Kingdom
Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation (CMAC) University of Strathclyde Glasgow United Kingdom
Funding
Engineering and Physical Sciences Research Council
References (59)
Show source-provided references
1. 10.1089/biores.2014.003310.1089/biores.2014.0033 ↗
2. 10.1186/1755-1536-4-2110.1186/1755-1536-4-21 ↗
3. The short amino‐acid‐sequence Pro‐His‐Ser‐Arg‐Asn in human fibronectin enhances cell‐adhesive function10.1016/S0021-9258(17)31456-4 ↗
4. 10.1016/j.biomaterials.2015.06.02510.1016/j.biomaterials.2015.06.025 ↗
5. 10.1021/acsami.5b0957610.1021/acsami.5b09576 ↗
6. 10.1016/j.biomaterials.2006.06.02710.1016/j.biomaterials.2006.06.027 ↗
7. 10.1016/S0142-9612(03)00343-010.1016/S0142-9612(03)00343-0 ↗
8. 10.1083/jcb.118.2.42110.1083/jcb.118.2.421 ↗
9. 10.1073/pnas.98.2.62010.1073/pnas.98.2.620 ↗
10. 10.1038/367193a010.1038/367193a0 ↗
11. 10.1371/journal.pone.010297410.1371/journal.pone.0102974 ↗
12. 10.1021/acs.biochem.5b0081810.1021/acs.biochem.5b00818 ↗
13. 10.1074/jbc.M50908220010.1074/jbc.M509082200 ↗
14. 10.7150/jca.2.47810.7150/jca.2.478 ↗
15. Anastellin, a fragment of the first type III repeat of fibronectin, inhibits extracellular signal‐regulated kinase and causes G1 arrest in human microvessel endothelial cells10.1158/0008-5472.148.65.1 ↗
16. 10.1158/1541-7786.MCR-08-019510.1158/1541-7786.MCR-08-0195 ↗
17. 10.1074/jbc.C110.17699010.1074/jbc.C110.176990 ↗
18. 10.1002/jbm.a.3023810.1002/jbm.a.30238 ↗
19. 10.1002/jbm.a.3002610.1002/jbm.a.30026 ↗
20. 10.1021/la034810a10.1021/la034810a ↗
21. 10.2174/15680260878379090110.2174/156802608783790901 ↗
22. 10.1021/ja042898o10.1021/ja042898o ↗
23. 10.1073/pnas.96.4.135110.1073/pnas.96.4.1351 ↗
24. 10.1002/jbm.a.3247310.1002/jbm.a.32473 ↗
25. 10.1177/175628720934130610.1177/1756287209341306 ↗
26. 10.1302/0301-620X.89B7.1914810.1302/0301-620X.89B7.19148 ↗
27. 10.1002/app.4053310.1002/app.40533 ↗
28. 10.1098/rsif.2010.055710.1098/rsif.2010.0557 ↗
29. 10.1002/jbm.a.3321910.1002/jbm.a.33219 ↗
30. 10.1016/j.cbpa.2011.04.02110.1016/j.cbpa.2011.04.021 ↗
31. 10.1021/la035771610.1021/la0357716 ↗
32. 10.1021/la301546v10.1021/la301546v ↗
33. 10.1021/jp502007710.1021/jp5020077 ↗
34. 10.1007/s13758-012-0024-z10.1007/s13758-012-0024-z ↗
35. 10.1039/C6RA01224H10.1039/C6RA01224H ↗
36. 10.1166/jamr.2010.103510.1166/jamr.2010.1035 ↗
37. 10.1007/978-1-4899-1176-6_110.1007/978-1-4899-1176-6_1 ↗
38. 10.1016/j.ijpharm.2012.09.00210.1016/j.ijpharm.2012.09.002 ↗
39. 10.1016/0043-1648(93)90191-N10.1016/0043-1648(93)90191-N ↗
40. 10.1021/ac951203m10.1021/ac951203m ↗
41. 10.1016/S0003-2670(00)82721-X10.1016/S0003-2670(00)82721-X ↗
42. 10.1016/0039-6028(85)90835-010.1016/0039-6028(85)90835-0 ↗
43. 10.1016/S0142-9612(03)00484-810.1016/S0142-9612(03)00484-8 ↗
44. 10.1016/S0927-7765(01)00236-310.1016/S0927-7765(01)00236-3 ↗
45. 10.1016/j.jcis.2003.11.05410.1016/j.jcis.2003.11.054 ↗
46. 10.1021/la048769310.1021/la0487693 ↗
47. 10.1039/a703017g10.1039/a703017g ↗
48. 10.1002/actp.1996.01047010710.1002/actp.1996.010470107 ↗
49. 10.1021/jp973084f10.1021/jp973084f ↗
50. 10.1002/jcc.2136710.1002/jcc.21367 ↗
51. 10.1063/1.240842010.1063/1.2408420 ↗
52. 10.1021/ct700200b10.1021/ct700200b ↗
53. 10.1002/jcc.54013080510.1002/jcc.540130805 ↗
54. 10.1063/1.47011710.1063/1.470117 ↗
55. 10.1021/ct700301q10.1021/ct700301q ↗
56. 10.1016/0021-9797(70)90055-X10.1016/0021-9797(70)90055-X ↗
57. 10.1016/j.colsurfb.2011.09.02110.1016/j.colsurfb.2011.09.021 ↗
58. 10.1021/ja065531n10.1021/ja065531n ↗
59. 10.1021/la203677810.1021/la2036778 ↗